Highlights from recent Life Science venture capital news.
July 31st, 2012 – Cambridge, MA
Mersana Therapeutics Raises $27M
Mersana Therapeutics, Inc. a biopharmaceutical company developing its Fleximer® antibody-drug conjugate (ADC) platform and pipeline of small molecule Fleximer conjugates, announced today that it has closed a $27million Series A-1 financing led by new investor New Enterprise Associates (NEA). Participation in the round also included new investor Pfizer Venture Investments and existing investors Fidelity Biosciences, ProQuest Investments, Rho Ventures and Harris and Harris Group.
July 31st, 2012 – South San Francisco, CA
CytomX Therapeutics Expands Series B Financing
CytomX Therapeutics, Inc., a biotechnology company creating a new generation of highly targeted antibody therapeutics, today announced that the company has expanded its Series B financing, bringing the total size of the round to $41 million. Canaan Partners led the financing and was joined by existing investors Third Rock Ventures and the Roche Venture Fund. In conjunction with the financing, Tim Shannon, M.D., of Canaan Partners will join CytomX’s board of directors.
August 3rd, 2012 – Ann Arbor, MI
Atterocor Raises $16M in Series A Funding
Atterocor, Inc., an Ann Arbor, Michigan-based developer of an innovative therapy for adrenal cancer, has raised $16m in Series A venture capital funding. The round was led by Frazier Healthcare and 5AM Ventures. The company intends to use the funding to accelerate development of its lead program to the clinic.
July 31st, 2012 – Macclesfield, UK
Dot Medical Raises £550K
Dot Medical Ltd, a Macclesfield, UK-based company that has manufactured a piece of equipment to treat a heart condition, has raised £550k in funding from The North West Fund for Biomedical, managed by SPARK Impact. The company intends to use the capital to expand the number of centres treating Atrial Fibrillation (AF), a heart condition that causes an irregular and often abnormally-fast heart rate.
July 30th, 2012 – Nes Ziona, Israel
NanoPass Secures Series B Investment
NanoPass Technologies Ltd., a pioneer in the development and commercialization of painless intradermal (skin) delivery solutions for vaccines and large molecules, announced today it has recently closed a new round of financing, led by Israel HealthCare Ventures (IHCV), a leading healthcare-dedicated venture capital fund, with the participation of current investors.
The capital raised will be used to accelerate the market penetration of NanoPass’ leading applications through additional licenses with pharmaceutical companies.
This Week In Venture Capital is brought to you by VM Index – Venture Capital made easier
VM Index is an online IT, Life Science, Biotech & Med Tech venture capital funding tool with expert data that enables companies to raise more money, faster and at a better valuation than they could otherwise.